Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro

Mol Biol Rep. 2022 Feb;49(2):1261-1271. doi: 10.1007/s11033-021-06953-2. Epub 2021 Nov 26.

Abstract

Background: The activation of toll like receptors (TLR) potentially affect the inflammatory tumor microenvironment and thus is associated with tumor growth or inhibition. Cabazitaxel (CAB) has been effectively used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the immune regulatory role of CAB in the tumor microenvironment is not clear. In this context, we for the first time assessed the immunotherapeutic role of CAB in the TLR3 signalling following activation of Poly I:C in mCRPC cells.

Methods and results: The cytotoxic and apoptotic effects of CAB with the induction of Poly I:C were determined by WST-1, Annexin V, acridine orange, RT-PCR analysis, ELISA assay and immunofluorescence staining in DU-145 mCRPC and HUVEC control cells. Our findings showed that CAB treatment with Poly I:C significantly suppressed the proliferation of DU-145 cells through the induction of apoptosis and caspase activation. Additionally, higher concentration of CAB mediated the activation of TLR3 via increased cytoplasmic and nuclear expression of TLR3, TICAM-1 and IRF-3 in mCRPC cells.

Conclusions: Co-treatment of CAB and Poly I:C was more effective in mCRPC cells with less toxicity in control cells. However, further investigations are required to elucidate the molecular mechanisms of TLRs signalling upon CAB treatment at the molecular level to further validate the immunotherapeutic efficacy of CAB in mCRPC.

Keywords: Apoptosis; Cabazitaxel; Taxanes; Toll like receptor 3; Toll like receptors.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Docetaxel / pharmacology
  • Humans
  • Immunotherapy / methods
  • Interferon Regulatory Factor-3
  • Male
  • Neoplasm Metastasis / genetics
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / immunology
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • Signal Transduction / drug effects
  • Taxoids / immunology
  • Taxoids / metabolism
  • Taxoids / pharmacology*
  • Toll-Like Receptor 3 / drug effects
  • Toll-Like Receptor 3 / metabolism*
  • Tumor Microenvironment / drug effects

Substances

  • Antineoplastic Agents
  • IRF3 protein, human
  • Interferon Regulatory Factor-3
  • TLR3 protein, human
  • Taxoids
  • Toll-Like Receptor 3
  • Docetaxel
  • cabazitaxel